ADP-ribosylating enterotoxins as vaccine adjuvants


    loading  Checking for direct PDF access through Ovid

Abstract

HighlightsCT and LT are the most potent, but also toxic, mucosal adjuvants known today.Enzymatic activity of the A1-subunit is the critical component for adjuvanticity.Adjuvanticity depends on Gsα in DCs and involves cell-mediated and humoral immunity.Detoxified derivatives using point mutations of the A-subunit retain adjuvanticity.Engineered fusion proteins, such as CTA1-DD, have been found safe and effective.Most infections are caused by pathogens that access the body at mucosal sites. Hence, development of mucosal vaccines to prevent local infection or invasion of pathogens appears highly warranted, especially since only mucosal immunization will stimulate strong local IgA responses and tissue resident memory CD4 and CD8 T cells. The most significant obstacle to developing such vaccines is the lack of approved adjuvants that can effectively and safely enhance relevant mucosal and systemic immune responses. The most potent mucosal adjuvants known today are the adenosine diphosphate (ADP)-ribosylating bacterial enterotoxins cholera toxin (CT) and Escherichia coli heat-labile toxins (LTs). Unfortunately, these molecules are also very toxic, which precludes their clinical use. However, much effort has been devoted to developing derivatives of these enterotoxins with low or no toxicity and retained adjuvant activity. Although it is fair to say that we know more about how these toxins affect the immune system than ever before, we still lack a detailed understanding of how and why these toxins are effective adjuvants. In the present review, we provide a state-of-the-art overview of the mechanism of action of the holotoxins and the strategies used for improving the toxin-based adjuvants.

    loading  Loading Related Articles